| major |
anatomic |
7 |
| minor |
anatomic |
34 |
| minor |
nonanatomic |
11 |
| no |
major |
5 |
| no |
minor |
13 |
| yes |
major |
2 |
| yes |
minor |
32 |
Univariate
Cirrhotic vs non-cirrhotic
Wilcoxon rank sum test with continuity correction: blood_loss by cirrhosis
| 204.5 |
0.05049 |
two.sided |
Wilcoxon rank sum test with continuity correction: tumor_number by cirrhosis
| 191 |
0.008711 * * |
two.sided |
Wilcoxon rank sum test with continuity correction: margin by cirrhosis
| 211 |
0.06739 |
two.sided |
Wilcoxon rank sum test with continuity correction: optime by cirrhosis
| 220.5 |
0.09522 |
two.sided |
Wilcoxon rank sum test with continuity correction: los by cirrhosis
| 313.5 |
0.8914 |
two.sided |
Wilcoxon rank sum test with continuity correction: afp by cirrhosis
| 205 |
0.09487 |
two.sided |
Univariate
Major/minor/anatomic
Wilcoxon rank sum test with continuity correction: blood_loss by op_type
| 192 |
0.3588 |
two.sided |
Wilcoxon rank sum test with continuity correction: blood_loss by anatomic
| 208 |
0.7014 |
two.sided |
Wilcoxon rank sum test with continuity correction: blood_loss by anatomic
| 165 |
0.5675 |
two.sided |
Survival
Median follow-up (reverse KM method): 41 months
Median OS(cohort): 89.3 months
Five year overall survival non-cirrhotic vs cirrhotic: 41% vs 34%

Cox
Fitting Proportional Hazards Regression Model: Surv(days_fu, dead) ~ tumor_number * (vascular_invasion + lymphatic_invasion)
| tumor_number |
-0.6912 |
0.501 |
1.05 |
-0.6581 |
0.5104 |
| vascular_invasionYes |
-2.54 |
0.07889 |
1.716 |
-1.48 |
0.139 |
| lymphatic_invasionYes |
5.915 |
370.7 |
2.291 |
2.582 |
0.009813 |
| tumor_number:vascular_invasionYes |
2.397 |
10.99 |
1.197 |
2.002 |
0.04526 |
| tumor_number:lymphatic_invasionYes |
-2.798 |
0.06096 |
1.441 |
-1.942 |
0.05214 |
Likelihood ratio test=20.36 on 5 df, p=0.001067222 n= 52, number of events= 17
| 11 |
1 |
Yes |
No |
0.69 |
| 12 |
2 |
Yes |
No |
3.78 |
| 13 |
3 |
Yes |
No |
20.82 |
| 14 |
4 |
Yes |
No |
114.63 |
| 15 |
5 |
Yes |
No |
631.27 |
Interpretting the Cox model is a little challenging due to the interactions between vascular invasion, lymphatic invasion and tumour number. Perhaps the easiest thing to do is just ignore lymphatic invasion and focus on tumour number and vascular invasion. As you can see with rows 11-16(tumor number 1-5, vascular invasion “yes”), increasing tumour number in the presence of vascular invasion is a very strong risk factor (the relative risk is next to it). The relative risk is compared with the sample “average” of tumour number (1.5).